Cochrane · systematic review · CD009769
Beclometasone for chronic obstructive pulmonary disease
De Coster, DA, Jones, M, Thakrar, N · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 14.3%Very low 4 · 28.6%Low 2 · 14.3%Moderate 5 · 35.7%High 1 · 7.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Beclometasone/LABA compared with LABA for COPD
Population: participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 20
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in FEV1 Beclometasone/LABA vs LABA | no estimate extracted | 1 study · 465 participants | High |
Mortality (all‐cause) (dichotomous Peto method) Beclometasone/LABA vs LABA | OR 7.48 [0.47, 120] | 1 study · 474 participants | Very low Downgraded: imprecision, indirectness |
Pneumonia: participants with at least one (dichotomous Peto odds ratios) Beclometasone/LABA vs LABA | OR 3.88 [0.78, 19.39] | 1 study · 474 participants | Low Downgraded: imprecision |
Exacerbations: participants with at least one (dichotomous) Beclometasone/LABA vs LABA | OR 0.96 [0.64, 1.45] | 1 study · 465 participants | Moderate Downgraded: imprecision |
Change in quality of life: SGRQ Scale: 0 to 100 Beclometasone/LABA vs LABA | no estimate extracted | 1 study · 465 participants | Moderate Downgraded: imprecision |
Adverse events: candidiasis Beclometasone/LABA vs LABA | no estimate extracted | 1 study · 474 participants | Moderate Downgraded: indirectness |
Withdrawal (all‐cause) Beclometasone/LABA vs LABA | OR 0.91 [0.54, 1.53] | 1 study · 474 participants | Moderate Downgraded: imprecision |
Beclometasone compared with placebo for COPD
Population: participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in FEV1 —at 2 years Beclometasone vs placebo | no estimate extracted | 1 study · 194 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Mortality (all‐cause) (dichotomous Peto method) Beclometasone vs placebo | OR 0.94 [0.26, 3.34] | 1 study · 194 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Pneumonia: participants with at least one (dichotomous Peto odds ratios) Beclometasone vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Exacerbations: participants with at least one (dichotomous) Beclometasone vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Symptoms: change in dyspnoea scale (Fletcher Scale) Fletcher dyspnoea scale (1 to 5) Beclometasone vs placebo | no estimate extracted | 1 study · 194 participants | Moderate Downgraded: publication bias |
Adverse events: candidiasis Beclometasone vs placebo | OR 1.41 [0.24, 8.31] | 1 study · 194 participants | Very low Downgraded: imprecision, indirectness, publication bias |
Withdrawal (all‐cause) Beclometasone vs placebo | OR 1.33 [0.83, 2.14] | 2 studies · 292 participants | Low Downgraded: imprecision, publication bias |